臨床研究等提出・公開システム

Safety, tolerability, and pharmacokinetics of single rising oral
doses of BI 1819479 in healthy male subjects (single-blind,
randomised, placebo-controlled, parallel group design)

A study in healthy men to test how well different doses of
BI 1819479 are tolerated

Suzuki Haruka

Boehringer Ingelheim

2-1-1, Osaki, Shinagawa-ku, Tokyo

medchiken.jp@boehringer-ingelheim.com

Kawahara Shizuko

Boehringer Ingelheim

2-1-1, Osaki, Shinagawa-ku, Tokyo

+81-120-189-779

medchiken.jp@boehringer-ingelheim.com

Not Recruiting

Aug. 05, 2022

Interventional

randomized controlled trial

single blind

placebo control

parallel assignment

treatment purpose

Healthy male subjects according to the assessment of the investigator, as based on a
complete medical history including a medical examination, vital signs (BP, PR), 12-lead
ECG, and clinical laboratory tests
Japanese ethnicity
BMI of 18.5 to 24.9 kg/m2 (inclusive)
Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation

Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 40 to 90 mmHg, or pulse rate outside the range of 40 to 99 bpm
Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
Any evidence of a concomitant disease assessed as clinically relevant by the investigator
Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders

Male

Idiopathic pulmonary fibrosis,Interstitial lung diseases with progressive phenotype,Systemic scleros

Administrate the study Drug(BI1819479 or Placebo)

The percentage of subjects with drug-related adverse events

+81-92-283-7701

Aug. 01, 2022

Yes

Researchers can refer to https://trials.boehringer-ingelheim.com/ to request access to raw data from our clinical studies.

none